# FUNDAMENTAL NEUROSURGICAL KNOWLEDGE ⭐⭐⭐
## ULTRA-GRANULAR SPECIFICATION FOR PATHOLOGY, PATHOPHYSIOLOGY, EPIDEMIOLOGY, GENETICS, AND TREATMENTS

**PURPOSE**: Comprehensive neurosurgical knowledge base covering all major pathologies with molecular genetics, epidemiology, evidence-based treatment algorithms, and outcomes data for clinical decision-making.

**SCOPE**: Brain tumors (primary, metastatic), cerebrovascular disease, spine pathology, trauma, infection, hydrocephalus, functional disorders, pediatric neurosurgery, peripheral nerve disorders.

**CLINICAL INTEGRATION**: WHO classification, molecular markers, treatment algorithms, surgical techniques, adjuvant therapies, prognosis, complications with incidence rates, clinical trial evidence.

---

## I. PRIMARY BRAIN TUMORS ⭐⭐⭐

### GLIOMAS ⭐⭐⭐:

#### GLIOBLASTOMA (GBM, WHO GRADE 4) ⭐⭐⭐:

├─ Epidemiology:
│   ├─ Incidence: 3.2 per 100,000 (most common primary malignant brain tumor in adults) ⭐
│   ├─ Age: Peak 65-75 years, median 64 years
│   ├─ Sex: Male:female ratio 1.6:1
│   └─ Survival: Median overall survival 15-18 months with standard treatment ⭐
│
├─ Pathophysiology:
│   ├─ Origin: Astrocytic lineage (from neural stem cells or dedifferentiation)
│   ├─ Growth pattern: Diffusely infiltrative (beyond imaging margins) ⭐
│   │   └─ Tumor cells extend 2-3 cm beyond enhancing edge (microscopic infiltration)
│   ├─ Angiogenesis: VEGF-driven neovascularization (leaky BBB → edema)
│   └─ Necrosis: Central necrosis with pseudopalisading cells (hypoxia-driven) ⭐
│
├─ Molecular genetics (WHO 2021 classification) ⭐⭐⭐:
│   ├─ IDH status (critical classification determinant):
│   │   ├─ IDH-wildtype glioblastoma ⭐⭐⭐:
│   │   │   ├─ 90% of glioblastomas (primary GBM, de novo)
│   │   │   ├─ Older patients (median 65 years)
│   │   │   ├─ Aggressive: Median survival 12-15 months
│   │   │   └─ Molecular features: EGFR amplification (50%), TERT promoter mutation (80%)
│   │   └─ IDH-mutant glioblastoma:
│   │       ├─ 10% of glioblastomas (secondary GBM, progression from lower-grade glioma)
│   │       ├─ Younger patients (median 45 years)
│   │       ├─ Better prognosis: Median survival 24-31 months ⭐
│   │       └─ Molecular features: TP53 mutation (80%), ATRX loss (70%)
│   ├─ MGMT promoter methylation ⭐⭐⭐:
│   │   ├─ Frequency: 40-45% of glioblastomas
│   │   ├─ Function: Methylation → silencing of MGMT DNA repair enzyme
│   │   ├─ Prognostic/predictive marker:
│   │   │   ├─ MGMT methylated: Better response to temozolomide (median survival 21-24 months) ⭐
│   │   │   └─ MGMT unmethylated: Poor response to TMZ (median survival 12-15 months)
│   │   └─ Treatment decision: Guides temozolomide use in elderly patients
│   ├─ EGFR alterations:
│   │   ├─ EGFR amplification: 40-50% (IDH-wildtype)
│   │   ├─ EGFRvIII mutation: 25-30% (constitutively active, targeted therapy trials)
│   │   └─ Clinical: Associated with worse prognosis
│   ├─ TERT promoter mutations: 70-80% (telomerase activation, immortalization)
│   └─ Other common alterations:
│       ├─ PTEN loss: 40% (PI3K pathway activation)
│       ├─ TP53 mutation: 30% (IDH-wildtype), 80% (IDH-mutant)
│       └─ CDKN2A/B deletion: 50-60% (cell cycle dysregulation)
│
├─ Clinical presentation:
│   ├─ Headache: 50% (morning headache, worse with Valsalva)
│   ├─ Seizures: 30-50% (focal or generalized)
│   ├─ Focal neurological deficits: 40-60%
│   │   ├─ Motor weakness: Frontal lobe, internal capsule involvement
│   │   ├─ Language deficits: Dominant hemisphere temporal/frontal
│   │   └─ Visual field defects: Occipital, temporal lobe (Meyer's loop)
│   ├─ Cognitive changes: Memory, executive dysfunction (frontal, corpus callosum)
│   └─ Symptom duration: Typically short (<3 months, rapid progression)
│
├─ Diagnostic workup ⭐⭐:
│   ├─ MRI brain with contrast:
│   │   ├─ T1 post-contrast: Ring enhancement (thick, irregular, nodular) ⭐
│   │   ├─ T2/FLAIR: Extensive vasogenic edema, "butterfly" pattern if crosses corpus callosum
│   │   ├─ DWI: Restricted diffusion at periphery (hypercellular), central necrosis (no restriction)
│   │   ├─ Perfusion (DSC): Elevated rCBV (>2.5-3.0) - angiogenesis marker ⭐
│   │   └─ MR spectroscopy: ↑Cho, ↓NAA, lactate peak, lipid peaks (necrosis)
│   ├─ Advanced imaging:
│   │   ├─ DTI tractography: Assess corticospinal tract, arcuate fasciculus (surgical planning)
│   │   ├─ fMRI: Motor and language mapping (eloquent cortex localization)
│   │   └─ Amino acid PET (FET, methionine): Tumor extent beyond contrast enhancement
│   └─ Tissue diagnosis: Stereotactic biopsy or resection (required for WHO classification)
│
├─ Treatment algorithm (Stupp protocol, standard of care) ⭐⭐⭐:
│   ├─ Surgery (maximal safe resection) ⭐⭐⭐:
│   │   ├─ Goal: Gross total resection (GTR) if feasible without unacceptable deficit
│   │   ├─ Extent of resection (EOR) impact on survival ⭐:
│   │   │   ├─ GTR (>98% resection): Median survival 17-21 months
│   │   │   ├─ Subtotal resection (STR, 80-98%): Median survival 14-16 months
│   │   │   └─ Biopsy only: Median survival 7-10 months
│   │   ├─ Adjuncts:
│   │   │   ├─ 5-ALA fluorescence-guided surgery: ↑ GTR rate (65% vs 36%), ↑ PFS ⭐
│   │   │   ├─ Awake craniotomy: Language/motor mapping for eloquent cortex tumors
│   │   │   ├─ Intraoperative MRI: Real-time resection assessment (↑ GTR rate)
│   │   │   └─ Neuronavigation: Stereotactic guidance, trajectory planning
│   │   ├─ Eloquent cortex tumors: Balance maximal resection with functional preservation
│   │   └─ Biopsy only: Poor performance status (KPS <70), extensive infiltration, multifocal
│   │
│   ├─ Adjuvant radiotherapy ⭐⭐:
│   │   ├─ Timing: Start within 4-6 weeks post-surgery
│   │   ├─ Dose: 60 Gy in 30 fractions (2 Gy per fraction) over 6 weeks ⭐
│   │   ├─ Target: GTV (gross tumor, resection cavity + residual enhancement) + 2-3 cm margin
│   │   ├─ Technique: Intensity-modulated RT (IMRT) or 3D conformal (spare hippocampus if possible)
│   │   └─ Elderly/poor performance: Hypofractionated RT (40 Gy in 15 fractions)
│   │
│   ├─ Concurrent and adjuvant temozolomide (Stupp protocol, 2005) ⭐⭐⭐:
│   │   ├─ Concurrent phase (with radiation):
│   │   │   ├─ Dose: 75 mg/m² daily (including weekends) for 6 weeks
│   │   │   └─ Side effects: Fatigue, mild nausea (rarely requires dose reduction)
│   │   ├─ Adjuvant phase (post-radiation):
│   │   │   ├─ Dose: 150-200 mg/m² days 1-5 of 28-day cycle
│   │   │   ├─ Duration: 6 cycles (extended to 12 cycles in some centers if tolerated)
│   │   │   └─ Side effects: Myelosuppression (monitor CBC), nausea, fatigue
│   │   ├─ Survival benefit (landmark Stupp trial) ⭐⭐:
│   │   │   ├─ RT + TMZ: Median survival 14.6 months, 2-year survival 26.5%
│   │   │   └─ RT alone: Median survival 12.1 months, 2-year survival 10.4%
│   │   │   ├─ Absolute survival benefit: 2.5 months (statistically significant)
│   │   └─ MGMT methylated patients: Median survival 23.4 months with RT+TMZ ⭐
│   │
│   └─ Tumor treating fields (TTFields, Optune) ⭐⭐:
│       ├─ Mechanism: Alternating electric fields (200 kHz) disrupt mitosis
│       ├─ Device: Transducer arrays on scalp (worn ≥18 hours/day)
│       ├─ Efficacy (EF-14 trial):
│       │   ├─ TTF + TMZ: Median survival 20.9 months, 5-year survival 13%
│       │   └─ TMZ alone: Median survival 16.0 months, 5-year survival 5%
│       ├─ Side effects: Scalp dermatitis (mild), compliance burden
│       └─ Indication: Newly diagnosed GBM (FDA approved), used with TMZ
│
├─ Recurrent glioblastoma treatment ⭐⭐:
│   ├─ Re-resection:
│   │   ├─ Indications: Focal recurrence, symptomatic mass effect, good performance status
│   │   └─ Survival: Median post-reoperation survival 8-10 months (selected patients)
│   ├─ Systemic therapy options:
│   │   ├─ Bevacizumab (anti-VEGF antibody):
│   │   │   ├─ Mechanism: Inhibits angiogenesis, normalizes BBB (↓ edema, ↓ contrast enhancement)
│   │   │   ├─ Dose: 10 mg/kg IV every 2 weeks
│   │   │   ├─ Response rate: 20-30% (radiographic response)
│   │   │   ├─ Progression-free survival: 3-4 months ⭐
│   │   │   ├─ Overall survival: NO improvement (pseudoresponse phenomenon)
│   │   │   └─ Side effects: Hypertension, proteinuria, hemorrhage risk, bowel perforation (<1%)
│   │   ├─ Lomustine (CCNU, nitrosourea):
│   │   │   ├─ Dose: 110 mg/m² every 6 weeks
│   │   │   └─ Survival: Similar to bevacizumab (median OS 8-9 months)
│   │   ├─ Rechallenge temozolomide: If initial response, long interval (>6 months)
│   │   └─ Clinical trials: Immunotherapy (checkpoint inhibitors - limited efficacy), CAR-T, vaccine
│   └─ Re-irradiation:
│       ├─ Stereotactic radiosurgery (SRS): Focal recurrence <3 cm
│       └─ Hypofractionated RT: Larger volume, 35-40 Gy in 10-15 fractions
│
└─ Prognosis and prognostic factors ⭐⭐⭐:
    ├─ Median overall survival: 15-18 months (standard treatment)
    ├─ 2-year survival: 25-30%
    ├─ 5-year survival: 5-10% ⭐
    ├─ Favorable prognostic factors ⭐:
    │   ├─ Molecular: IDH-mutant, MGMT methylated
    │   ├─ Clinical: Younger age (<50), good performance status (KPS ≥70)
    │   ├─ Surgical: Gross total resection (>98%)
    │   └─ Treatment: Completion of Stupp protocol (RT + TMZ)
    └─ Poor prognostic factors:
        ├─ Molecular: IDH-wildtype, MGMT unmethylated
        ├─ Clinical: Older age (>70), poor KPS (<70), multifocal disease
        └─ Surgical: Biopsy only, eloquent location precluding resection

---

#### OLIGODENDROGLIOMA (WHO GRADE 2-3) ⭐⭐:

├─ Epidemiology:
│   ├─ Incidence: 0.3 per 100,000 (5% of primary brain tumors)
│   ├─ Age: Peak 40-50 years (younger than glioblastoma)
│   └─ Survival: Median 10-15 years (grade 2), 5-8 years (grade 3) ⭐
│
├─ Molecular genetics (WHO 2021 - REQUIRED for diagnosis) ⭐⭐⭐:
│   ├─ IDH mutation: REQUIRED (IDH1 R132H most common, 90%) ⭐⭐
│   │   └─ All oligodendrogliomas are IDH-mutant by definition
│   ├─ 1p/19q codeletion ⭐⭐⭐:
│   │   ├─ REQUIRED for oligodendroglioma diagnosis (pathognomonic)
│   │   ├─ Mechanism: Unbalanced translocation t(1;19)(q10;p10)
│   │   ├─ Frequency: 100% (by definition in WHO 2021)
│   │   └─ Significance: Better prognosis, chemosensitivity (PCV response) ⭐
│   ├─ TERT promoter mutation: 90-95% (coexists with IDH + 1p/19q)
│   └─ CIC and FUBP1 mutations: 60-80% (specific to oligodendroglioma)
│
├─ Pathology:
│   ├─ Histology: "Fried egg" appearance (round nuclei, clear perinuclear halo) ⭐
│   ├─ Calcification: 70-90% (visible on CT, "chicken wire" vasculature)
│   └─ Grade 3 (anaplastic) criteria: ↑ mitoses, ↑ cellularity, microvascular proliferation
│
├─ Clinical presentation:
│   ├─ Seizures: 70-90% (most common presentation, often long history) ⭐
│   ├─ Slow growth: Years of symptoms (seizures, headache)
│   └─ Location: Frontal lobe (50-65%), involving cortex and white matter ⭐
│
├─ Imaging:
│   ├─ CT: Hypodense mass, calcification (70-90%), cortical involvement
│   ├─ MRI:
│   │   ├─ T1: Hypointense, no enhancement (grade 2) or patchy enhancement (grade 3)
│   │   ├─ T2/FLAIR: Hyperintense, cortical ribbon thickening
│   │   └─ Imaging mimics: Low-grade astrocytoma (need molecular diagnosis)
│
├─ Treatment ⭐⭐:
│   ├─ Surgery: Maximal safe resection (GTR associated with better outcomes)
│   ├─ Observation (grade 2, low-risk):
│   │   ├─ Indications: GTR, young age, asymptomatic (after seizure control)
│   │   └─ Close surveillance: MRI every 3-6 months
│   ├─ Radiation + chemotherapy (grade 2 high-risk, grade 3) ⭐⭐:
│   │   ├─ RTOG 9802 trial (grade 2 high-risk = age ≥40 OR subtotal resection):
│   │   │   ├─ RT + PCV: Median survival 13.3 years
│   │   │   └─ RT alone: Median survival 7.8 years
│   │   │   └─ Conclusion: RT + PCV superior for high-risk grade 2 ⭐
│   │   ├─ Radiation: 54 Gy in 30 fractions (lower dose than GBM)
│   │   ├─ PCV chemotherapy (procarbazine, CCNU, vincristine):
│   │   │   ├─ Standard regimen: 6 cycles, 8-week cycles
│   │   │   └─ Side effects: Myelosuppression, neuropathy (vincristine), nausea
│   │   └─ Temozolomide alternative:
│   │       ├─ CODEL trial (ongoing): RT + TMZ vs RT + PCV (non-inferiority design)
│   │       └─ Practice: TMZ often used (better tolerability than PCV)
│   └─ Recurrence: Re-resection, temozolomide, PCV rechallenge, clinical trials
│
└─ Prognosis ⭐⭐:
    ├─ Grade 2: Median survival 10-15 years, 10-year survival 60-80%
    ├─ Grade 3: Median survival 5-8 years, 10-year survival 40-50%
    └─ Better than astrocytomas of equivalent grade (due to 1p/19q codeletion)

---

#### DIFFUSE ASTROCYTOMA, IDH-MUTANT (WHO GRADE 2-4) ⭐⭐:

├─ Molecular genetics ⭐⭐:
│   ├─ IDH mutation: REQUIRED (IDH1 R132H or IDH2)
│   ├─ NO 1p/19q codeletion (distinguishes from oligodendroglioma)
│   ├─ TP53 mutation: 80-90% (tumor suppressor loss)
│   ├─ ATRX loss: 70-90% (chromatin remodeling, telomere maintenance)
│   └─ Progression: Grade 2 → Grade 3 (anaplastic) → Grade 4 (secondary GBM) over years
│
├─ Clinical:
│   ├─ Age: Younger (median 35-45 years)
│   ├─ Presentation: Seizures (60-85%), gradual neurological decline
│   └─ Location: Frontal, temporal lobes (cortical and subcortical infiltration)
│
├─ Treatment:
│   ├─ Surgery: Maximal safe resection
│   ├─ Grade 2: Observation vs RT (based on risk factors), consider TMZ
│   ├─ Grade 3-4: RT + TMZ (similar to glioblastoma protocol)
│   └─ Prognosis:
│       ├─ Grade 2: Median survival 8-10 years
│       ├─ Grade 3: Median survival 3-5 years
│       └─ Grade 4 (IDH-mutant GBM): Median survival 24-31 months (better than IDH-wildtype)

---

### MENINGIOMA ⭐⭐⭐:

├─ Epidemiology:
│   ├─ Incidence: 8 per 100,000 (most common primary brain tumor, 30-40% of all intracranial tumors) ⭐
│   ├─ Age: Peak 60-70 years, rare in children
│   ├─ Sex: Female:male ratio 2-3:1 (progesterone receptor expression) ⭐
│   └─ Location: Parasagittal/falx (25%), convexity (20%), sphenoid wing (20%), olfactory groove, CPA
│
├─ Pathophysiology:
│   ├─ Origin: Arachnoid cap cells (meningothelial cells)
│   ├─ Growth: Slow-growing, extra-axial (displaces brain, CSF cleft) ⭐
│   ├─ Dural attachment: Broad dural base, "dural tail" sign (reactive enhancement)
│   └─ Hyperostosis: Bone invasion/thickening in 20-30% (sphenoid wing)
│
├─ Molecular genetics ⭐⭐:
│   ├─ NF2 mutation/loss (chromosome 22q):
│   │   ├─ Frequency: 40-60% (sporadic meningiomas)
│   │   ├─ NF2 syndrome: Multiple meningiomas, bilateral vestibular schwannomas
│   │   └─ Associated with higher-grade tumors
│   ├─ Other mutations (non-NF2 meningiomas):
│   │   ├─ AKT1 E17K: 10% (meningothelial meningiomas, skull base)
│   │   ├─ SMO mutations: 5% (hedgehog pathway, potential drug target)
│   │   ├─ TRAF7 mutations: 20-25% (often with AKT1 or KLF4 mutations)
│   │   └─ BAP1 loss: Associated with higher grade, rhabdoid features
│   ├─ Chromosomal alterations predicting recurrence:
│   │   └─ 1p deletion, 9p deletion, 10q deletion: Higher recurrence risk
│   └─ Progesterone receptor (PR): 60-80% positive (grade 1), correlates with better prognosis
│
├─ WHO grading (2021) ⭐⭐⭐:
│   ├─ Grade 1 (benign, 80-85%):
│   │   ├─ Subtypes: Meningothelial, fibrous, transitional, psammomatous, secretory
│   │   ├─ Growth: Slow, recurrence rate 5-7% at 5 years (after GTR)
│   │   └─ Imaging: Homogeneous enhancement, well-circumscribed
│   ├─ Grade 2 (atypical, 10-15%):
│   │   ├─ Criteria ⭐:
│   │   │   ├─ ≥4 mitoses per 10 high-power fields, OR
│   │   │   ├─ ≥3 of the following: ↑ cellularity, small cells, prominent nucleoli, sheet-like growth, necrosis
│   │   │   └─ Brain invasion (even if otherwise grade 1 histology)
│   │   ├─ Recurrence: 30-40% at 5 years (after GTR)
│   │   └─ Treatment: Surgery + consideration of adjuvant radiation
│   └─ Grade 3 (anaplastic/malignant, 1-3%):
│       ├─ Criteria: ≥20 mitoses per 10 HPF, OR overtly malignant (sarcoma, carcinoma-like)
│       ├─ Subtypes: Papillary, rhabdoid (aggressive, poor prognosis)
│       ├─ Recurrence: 50-80% at 5 years
│       └─ Treatment: Surgery + radiation therapy (high dose)
│
├─ Clinical presentation ⭐⭐:
│   ├─ Asymptomatic: 30-40% (incidental finding on imaging)
│   ├─ Seizures: 20-50% (convexity, parasagittal locations)
│   ├─ Focal neurological deficits:
│   │   ├─ Motor weakness: Parasagittal (leg > arm if superior sagittal sinus)
│   │   ├─ Visual changes: Sphenoid wing, olfactory groove (optic nerve compression)
│   │   ├─ Cranial neuropathies: CPA (CN V, VII, VIII), cavernous sinus (CN III, IV, VI, V1, V2)
│   │   └─ Anosmia: Olfactory groove meningioma (Foster Kennedy syndrome: ipsilateral optic atrophy + contralateral papilledema)
│   ├─ Headache: 35-50% (mass effect, ↑ ICP)
│   └─ Cognitive changes: Frontal lobe meningiomas (executive dysfunction, personality changes)
│
├─ Imaging (MRI with contrast) ⭐⭐:
│   ├─ T1 post-contrast: Intense homogeneous enhancement (highly vascular) ⭐
│   ├─ Extra-axial features ⭐:
│   │   ├─ CSF cleft: Between tumor and brain (vs intra-axial lesion)
│   │   ├─ Dural tail: Linear dural enhancement extending from tumor base (60-70%)
│   │   ├─ Buckling of gray-white junction: Brain surface deformed inward
│   │   └─ Hyperostosis: Adjacent bone thickening (CT better for bone)
│   ├─ T2/FLAIR: Variable signal (fibrous = hypointense, meningothelial = isointense)
│   ├─ Peritumoral edema: Present in 40-60% (worse with larger tumors, convexity location)
│   └─ Vascular imaging (CTA, MRA, DSA):
│       ├─ Arterial supply: ECA branches (middle meningeal artery most common)
│       └─ Venous sinus involvement: Assess patency (critical for surgical planning)
│
├─ Treatment ⭐⭐⭐:
│   ├─ Observation:
│   │   ├─ Indications: Asymptomatic, small (<3 cm), elderly, significant comorbidities
│   │   ├─ Growth rate: 1-2 mm/year (average), 10% remain stable indefinitely
│   │   └─ Surveillance: MRI every 6-12 months initially, then annually if stable
│   │
│   ├─ Surgery (primary treatment for symptomatic meningiomas) ⭐⭐⭐:
│   │   ├─ Goals: Gross total resection (GTR) including involved dura and bone (Simpson grade I-II)
│   │   ├─ Simpson grading system (predicts recurrence) ⭐:
│   │   │   ├─ Grade I: Complete tumor + dural attachment + abnormal bone removal
│   │   │   │   └─ Recurrence: 9% at 10 years
│   │   │   ├─ Grade II: Complete tumor + dural coagulation (not excised)
│   │   │   │   └─ Recurrence: 19% at 10 years
│   │   │   ├─ Grade III: Complete tumor, no dural treatment
│   │   │   │   └─ Recurrence: 29% at 10 years
│   │   │   ├─ Grade IV: Subtotal resection (STR)
│   │   │   │   └─ Recurrence: 40% at 10 years
│   │   │   └─ Grade V: Decompression only (no tumor removal)
│   │   ├─ Surgical approaches by location:
│   │   │   ├─ Convexity: Craniotomy over tumor, devascularize from dural base first
│   │   │   ├─ Parasagittal: Risk of venous sinus injury, preoperative embolization if large
│   │   │   ├─ Sphenoid wing: Pterional approach, carotid artery proximity
│   │   │   ├─ Olfactory groove: Bifrontal craniotomy, preserve olfactory nerves
│   │   │   └─ Posterior fossa (CPA): Retrosigmoid approach, CN preservation critical
│   │   ├─ Preoperative embolization:
│   │   │   ├─ Indications: Large meningiomas (>3-4 cm), highly vascular on DSA
│   │   │   ├─ Timing: 24-72 hours before surgery (reduces intraoperative bleeding)
│   │   │   └─ Agent: Polyvinyl alcohol (PVA) particles, Onyx
│   │   ├─ Complications:
│   │   │   ├─ Venous sinus occlusion: Venous infarction (if sinus involved and resected without patent collaterals)
│   │   │   ├─ Cranial nerve injury: CPA meningiomas (CN VII, VIII), cavernous sinus (CN III-VI)
│   │   │   ├─ CSF leak: Skull base meningiomas (15-20%)
│   │   │   └─ Hemorrhage: Intraoperative bleeding (meningiomas are highly vascular)
│   │   └─ Outcomes:
│   │       ├─ GTR rate: 80-90% (convexity), 50-70% (skull base)
│   │       └─ Mortality: <2% (convexity), 2-5% (skull base)
│   │
│   ├─ Radiation therapy ⭐⭐:
│   │   ├─ Indications:
│   │   │   ├─ Adjuvant: Grade 2-3 meningiomas (after resection)
│   │   │   ├─ Primary: Unresectable (cavernous sinus, optic nerve sheath), medical comorbidities
│   │   │   └─ Recurrent: Progressive disease after surgery
│   │   ├─ Stereotactic radiosurgery (SRS, single fraction):
│   │   │   ├─ Indications: Small (<3 cm), surgically inaccessible (cavernous sinus, optic sheath)
│   │   │   ├─ Dose: 12-16 Gy (single fraction) to tumor margin
│   │   │   ├─ Tumor control: 90-95% at 5 years (grade 1), 60-70% (grade 2-3)
│   │   │   └─ Complications: Cranial neuropathy (5-10%), radiation necrosis (rare)
│   │   ├─ Fractionated stereotactic RT (FSRT):
│   │   │   ├─ Indications: Larger tumors (>3 cm), near optic apparatus (optic tolerance <8 Gy single fraction)
│   │   │   ├─ Dose: 50-54 Gy in 25-30 fractions (1.8-2 Gy per fraction)
│   │   │   └─ Tumor control: 85-90% at 5 years
│   │   └─ Adjuvant RT for grade 2-3:
│   │       ├─ EORTC 22042 trial (ongoing): RT vs observation for atypical meningioma
│   │       └─ Current practice: RT recommended for grade 3, considered for grade 2 with STR
│   │
│   └─ Systemic therapy (limited role):
│       ├─ Indications: Recurrent, refractory to surgery/RT, grade 3
│       ├─ Agents (limited efficacy):
│       │   ├─ Somatostatin analogs (octreotide): 10% response rate (somatostatin receptor-positive tumors)
│       │   ├─ Bevacizumab: Case reports, limited data
│       │   └─ mTOR inhibitors (everolimus): NF2-associated meningiomas, phase II trials
│       └─ Clinical trials: SMO inhibitors (SMO-mutant tumors), AKT inhibitors
│
└─ Prognosis ⭐⭐:
    ├─ Grade 1: 10-year survival >90%, recurrence 5-10% (after GTR)
    ├─ Grade 2: 10-year survival 60-75%, recurrence 30-40%
    ├─ Grade 3: 10-year survival 30-50%, recurrence 50-80%
    └─ Recurrence factors: Higher grade, Simpson grade III-V resection, brain invasion, chromosomal deletions

---

### PITUITARY ADENOMAS ⭐⭐:

├─ Epidemiology:
│   ├─ Prevalence: 15-20% of population (autopsy/imaging studies) - most clinically silent
│   ├─ Clinically significant: 1-2 per 100,000 per year
│   └─ Age: Any age, peak 30-60 years
│
├─ Classification ⭐⭐:
│   ├─ Size:
│   │   ├─ Microadenoma: <10 mm (confined to sella)
│   │   └─ Macroadenoma: ≥10 mm (may extend suprasellar, parasellar)
│   ├─ Functional status:
│   │   ├─ Functioning (hormone-secreting, 60%):
│   │   │   ├─ Prolactinoma: 40% of adenomas (most common functioning type) ⭐
│   │   │   ├─ GH-secreting: 20% (acromegaly)
│   │   │   ├─ ACTH-secreting: 10-15% (Cushing's disease)
│   │   │   └─ TSH, FSH/LH-secreting: Rare (<5%)
│   │   └─ Non-functioning (40%): Clinically silent gonadotroph adenomas (present with mass effect)
│   └─ Invasiveness: Knosp grade (cavernous sinus invasion, 0-4 based on ICA encasement)
│
├─ Molecular genetics:
│   ├─ Familial syndromes (<5%):
│   │   ├─ MEN1 (multiple endocrine neoplasia type 1): Pituitary adenoma (40%), parathyroid, pancreatic NETs
│   │   ├─ MEN4 (CDKN1B mutation): Pituitary adenoma, parathyroid
│   │   ├─ Familial isolated pituitary adenoma (FIPA): AIP gene mutation
│   │   └─ Carney complex: GH-secreting adenomas, cardiac myxomas
│   └─ Sporadic mutations: GNAS (GH-secreting, 40%), USP8 (ACTH-secreting, 35%)
│
├─ Clinical presentation by type ⭐⭐⭐:
│   ├─ Prolactinoma:
│   │   ├─ Women: Amenorrhea, galactorrhea, infertility (microadenomas, diagnosed early)
│   │   ├─ Men: Hypogonadism, erectile dysfunction, decreased libido (macroadenomas, late diagnosis)
│   │   ├─ Prolactin level: Correlates with tumor size (>200 ng/mL suggests macroadenoma) ⭐
│   │   └─ "Stalk effect": Non-functioning adenoma compresses stalk → mild ↑ PRL (20-100 ng/mL)
│   ├─ Acromegaly (GH excess):
│   │   ├─ Features: Frontal bossing, prognathism, large hands/feet, macroglossia
│   │   ├─ Comorbidities: Hypertension, diabetes, cardiomyopathy, sleep apnea, colon polyps
│   │   ├─ Diagnosis: Elevated IGF-1, failed GH suppression on OGTT (<1 ng/mL)
│   │   └─ Mortality: 2-3x general population (cardiovascular disease)
│   ├─ Cushing's disease (ACTH excess):
│   │   ├─ Features: Central obesity, moon facies, buffalo hump, striae, proximal myopathy
│   │   ├─ Diagnosis: ↑ 24h urine cortisol, failed dexamethasone suppression, ↑ ACTH
│   │   ├─ Localization: MRI (microadenoma in 50-60%), bilateral IPSS (inferior petrosal sinus sampling)
│   │   └─ Mortality: 4-5x general population (cardiovascular, infection)
│   └─ Non-functioning adenoma (mass effect):
│       ├─ Visual field defects: Bitemporal hemianopsia (chiasm compression) ⭐
│       ├─ Hypopituitarism: GH deficiency (most common), then FSH/LH, TSH, ACTH (sequential loss)
│       ├─ Headache: 40-60% (dural stretch)
│       └─ Pituitary apoplexy: Acute hemorrhage → sudden headache, vision loss, hypopituitarism (surgical emergency)
│
├─ Diagnostic workup:
│   ├─ Hormonal evaluation:
│   │   ├─ Prolactin, GH, IGF-1, ACTH, cortisol (8am), TSH, free T4, FSH, LH, testosterone/estradiol
│   │   └─ Dynamic tests: OGTT (acromegaly), dexamethasone suppression (Cushing's)
│   ├─ MRI pituitary with contrast (dedicated protocol):
│   │   ├─ Sequences: Thin-slice (2-3 mm) coronal and sagittal T1 pre/post-contrast, T2
│   │   ├─ Microadenoma: Hypointense on T1 (delayed enhancement vs normal pituitary) ⭐
│   │   ├─ Macroadenoma: Suprasellar extension ("snowman" appearance), cavernous sinus invasion
│   │   └─ Knosp grade (cavernous sinus invasion): 0-2 (no medial ICA encasement, resectable), 3-4 (medial ICA encasement, not fully resectable)
│   └─ Visual field testing: Formal perimetry (if suprasellar extension)
│
├─ Treatment ⭐⭐⭐:
│   ├─ PROLACTINOMA (medical management first-line) ⭐⭐⭐:
│   │   ├─ Dopamine agonists:
│   │   │   ├─ Cabergoline (first-line):
│   │   │   │   ├─ Mechanism: D2 receptor agonist (↓ prolactin synthesis, tumor shrinkage)
│   │   │   │   ├─ Dose: Start 0.25 mg twice weekly, titrate to 0.5-1 mg twice weekly
│   │   │   │   ├─ Efficacy: Normalize PRL 80-90%, tumor shrinkage 70-90% ⭐
│   │   │   │   └─ Side effects: Nausea, orthostatic hypotension, impulse control disorders (rare)
│   │   │   └─ Bromocriptine (alternative):
│   │   │       ├─ Dose: 2.5-15 mg daily (divided doses)
│   │   │       └─ Efficacy: Normalize PRL 70-80% (less effective than cabergoline)
│   │   ├─ Surgery (transsphenoidal):
│   │   │   ├─ Indications: Dopamine agonist resistance/intolerance, CSF leak, visual compromise
│   │   │   ├─ Remission: 70-90% (microadenomas), 30-50% (macroadenomas)
│   │   │   └─ Recurrence: 20-50% over 10 years
│   │   └─ Radiation: Rare (refractory cases)
│   │
│   ├─ ACROMEGALY and CUSHING'S DISEASE (surgery first-line) ⭐⭐:
│   │   ├─ Transsphenoidal surgery:
│   │   │   ├─ Approach: Endoscopic endonasal (preferred) or microscopic sublabial
│   │   │   ├─ Remission rates ⭐:
│   │   │   │   ├─ Microadenoma: 70-90% biochemical remission
│   │   │   │   ├─ Macroadenoma: 40-60% remission (worse if cavernous sinus invasion)
│   │   │   │   └─ Cushing's disease: 70-90% remission (experienced centers)
│   │   │   ├─ Complications:
│   │   │   │   ├─ CSF leak: 3-10% (higher with extended approaches)
│   │   │   │   ├─ Hypopituitarism: 5-15% (new deficits)
│   │   │   │   ├─ Diabetes insipidus: Transient 10-20%, permanent 1-2%
│   │   │   │   ├─ Vascular injury (ICA, cavernous sinus): <1%
│   │   │   │   └─ Meningitis: 1-2%
│   │   │   └─ Recurrence: 10-20% over 10 years
│   │   ├─ Medical therapy (adjuvant or primary if surgery failed):
│   │   │   ├─ Acromegaly:
│   │   │   │   ├─ Somatostatin analogs: Octreotide LAR, lanreotide (normalize IGF-1 in 50-70%)
│   │   │   │   ├─ GH receptor antagonist: Pegvisomant (normalize IGF-1 in 90%, no tumor shrinkage)
│   │   │   │   └─ Dopamine agonist: Cabergoline (modest effect, 10-30% remission)
│   │   │   └─ Cushing's disease:
│   │   │       ├─ Pasireotide (somatostatin analog): Normalize UFC 15-25%
│   │   │       ├─ Ketoconazole, metyrapone: Adrenal enzyme inhibitors (cortisol synthesis)
│   │   │       └─ Bilateral adrenalectomy: Last resort (definitive, requires lifelong replacement)
│   │   └─ Radiation therapy:
│   │       ├─ Indications: Surgical failure, residual/recurrent disease
│   │       ├─ SRS (stereotactic radiosurgery): 20-25 Gy to margin (single fraction)
│   │       ├─ Biochemical control: 50-60% at 10 years (delayed effect, takes years)
│   │       └─ Complications: Hypopituitarism (50-60% at 10 years), optic neuropathy (<2%)
│   │
│   └─ NON-FUNCTIONING ADENOMAS ⭐⭐:
│       ├─ Observation:
│       │   ├─ Indications: Incidental microadenoma, no visual compromise, normal pituitary function
│       │   └─ Surveillance: MRI every 6-12 months initially, then annually if stable
│       ├─ Surgery:
│       │   ├─ Indications: Visual field defects, symptomatic mass effect, pituitary apoplexy
│       │   ├─ Goal: Decompress optic chiasm, preserve pituitary function
│       │   ├─ Gross total resection: 50-70% (limited by cavernous sinus invasion)
│       │   └─ Visual improvement: 70-90% (if preoperative deficit)
│       └─ Radiation: Adjuvant for residual/recurrent disease (tumor control 90-95% at 10 years)
│
└─ Prognosis:
    ├─ Prolactinoma: Excellent (medical management effective)
    ├─ Acromegaly: Reduced life expectancy if uncontrolled (normalize with treatment)
    ├─ Cushing's: Excess mortality if uncontrolled, improves with remission
    └─ Non-functioning: Recurrence 10-20% at 10 years (after GTR), higher if STR

---

## II. METASTATIC BRAIN TUMORS ⭐⭐⭐:

├─ Epidemiology:
│   ├─ Incidence: 150,000-200,000 per year in US (most common intracranial tumor) ⭐
│   ├─ Frequency: 10x more common than primary brain tumors
│   ├─ Primary sources (in order):
│   │   ├─ Lung cancer: 40-50% (most common, especially small cell and adenocarcinoma) ⭐
│   │   ├─ Breast cancer: 15-20%
│   │   ├─ Melanoma: 10% (highest propensity to metastasize to brain, 40-60% of melanoma patients)
│   │   ├─ Renal cell carcinoma: 5-10%
│   │   ├─ Colorectal cancer: 5%
│   │   └─ Unknown primary: 10-15%
│   └─ Distribution: 80% supratentorial (cortico-medullary junction, watershed zones), 20% posterior fossa
│
├─ Pathophysiology:
│   ├─ Hematogenous spread: Via arterial circulation → lodge in small vessels at gray-white junction ⭐
│   ├─ Multiple lesions: 50-60% of patients (vs 40-50% solitary)
│   └─ Peritumoral edema: Extensive vasogenic edema (disrupted BBB)
│
├─ Clinical presentation:
│   ├─ Headache: 40-50%
│   ├─ Focal neurological deficits: 30-40% (location-dependent)
│   ├─ Seizures: 15-25% (cortical location)
│   ├─ Cognitive changes: 30-40%
│   └─ Acute presentation: Hemorrhage (melanoma, renal cell, choriocarcinoma, thyroid) - 10-15%
│
├─ Imaging (MRI with contrast) ⭐⭐:
│   ├─ T1 post-contrast: Ring enhancement (smooth, thin) ⭐
│   ├─ Multiple lesions: At gray-white junction (cortico-medullary junction) ⭐
│   ├─ Disproportionate edema: Large vasogenic edema relative to lesion size
│   ├─ Restricted diffusion: May be present in center (hypercellularity)
│   └─ Hemorrhage: T1 hyperintense (methemoglobin), "blooming" on GRE/SWI (melanoma, RCC)
│
├─ Treatment ⭐⭐⭐:
│   ├─ Corticosteroids:
│   │   ├─ Dexamethasone: 4-16 mg/day (reduces vasogenic edema, symptoms)
│   │   └─ Response: Rapid (24-48 hours), symptomatic improvement
│   │
│   ├─ Surgery (resection) ⭐⭐:
│   │   ├─ Indications:
│   │   │   ├─ Solitary metastasis (or limited metastases, 1-3 lesions, all accessible)
│   │   │   ├─ Controlled or controllable systemic disease
│   │   │   ├─ Good performance status (KPS ≥70)
│   │   │   ├─ Symptomatic mass effect
│   │   │   └─ Unknown primary (tissue diagnosis)
│   │   ├─ Patchell trial (1990, landmark) ⭐⭐:
│   │   │   ├─ Surgery + WBRT vs WBRT alone (solitary metastasis)
│   │   │   ├─ Median survival: 40 weeks vs 15 weeks (surgery + WBRT superior) ⭐
│   │   │   ├─ Recurrence at surgical site: 10% vs 46%
│   │   │   └─ Conclusion: Surgery + WBRT superior for solitary metastasis
│   │   ├─ Surgical technique:
│   │   │   ├─ En bloc resection with surrounding margin (circumferential dissection)
│   │   │   └─ Goal: Complete resection (positive margins increase local recurrence)
│   │   └─ Post-op radiation: SRS to cavity (preferred) or WBRT
│   │
│   ├─ Stereotactic radiosurgery (SRS) ⭐⭐⭐:
│   │   ├─ Indications:
│   │   │   ├─ Limited brain metastases (1-4 lesions, some centers up to 10)
│   │   │   ├─ Small lesions (<3 cm, ideal <2 cm)
│   │   │   ├─ Deep/eloquent location (surgery high-risk)
│   │   │   ├─ Controlled systemic disease
│   │   │   └─ Radioresistant histologies (melanoma, renal cell)
│   │   ├─ Dose (single fraction, based on size):
│   │   │   ├─ <2 cm: 20-24 Gy to tumor margin
│   │   │   ├─ 2-3 cm: 18 Gy
│   │   │   └─ 3-4 cm: 15 Gy (>4 cm usually not treated with single-fraction SRS)
│   │   ├─ Local control: 80-95% at 1 year ⭐
│   │   ├─ Survival: Median 8-11 months (limited metastases), up to 20+ months (favorable patients)
│   │   ├─ Complications:
│   │   │   ├─ Radiation necrosis: 5-10% (symptomatic, may require resection or bevacizumab)
│   │   │   └─ Edema: Transient worsening (dexamethasone management)
│   │   └─ SRS vs WBRT (multiple trials):
│   │       ├─ Local control: SRS superior to WBRT alone
│   │       ├─ Overall survival: No difference (systemic disease determines survival)
│   │       └─ Neurocognitive outcomes: SRS preserves cognition better than WBRT ⭐
│   │
│   ├─ Whole brain radiation therapy (WBRT) ⭐:
│   │   ├─ Indications:
│   │   │   ├─ Multiple metastases (>4-10, not amenable to SRS)
│   │   │   ├─ Leptomeningeal disease
│   │   │   ├─ Small cell lung cancer (prophylactic)
│   │   │   └─ Adjuvant after surgery or SRS (decreasing use)
│   │   ├─ Dose: 30 Gy in 10 fractions (most common) or 37.5 Gy in 15 fractions
│   │   ├─ Efficacy:
│   │   │   ├─ Median survival: 3-6 months (depends on RPA class)
│   │   │   ├─ Intracranial control: Reduces distant brain failure vs SRS alone
│   │   │   └─ Salvage: SRS can be given for progression after WBRT
│   │   ├─ Neurotoxicity ⭐:
│   │   │   ├─ Acute: Fatigue, alopecia (universal), headache
│   │   │   ├─ Subacute: Somnolence syndrome (1-2 months post-RT)
│   │   │   └─ Delayed: Neurocognitive decline (memory, executive function), leukoencephalopathy
│   │   └─ Hippocampal-avoidance WBRT: Reduces memory decline (NRG CC001 trial)
│   │
│   └─ Systemic therapy:
│       ├─ Historically: Limited CNS penetration (intact BBB in some areas)
│       ├─ Modern agents with CNS activity:
│       │   ├─ Targeted therapy:
│       │   │   ├─ EGFR inhibitors (osimertinib): NSCLC with EGFR mutation (CNS response 70-80%) ⭐
│       │   │   ├─ ALK inhibitors (alectinib, brigatinib): ALK+ NSCLC (CNS response 60-80%)
│       │   │   └─ BRAF/MEK inhibitors (dabrafenib/trametinib): BRAF V600E melanoma (CNS response 50-60%)
│       │   └─ Immunotherapy:
│       │       ├─ Checkpoint inhibitors (pembrolizumab, nivolumab): Melanoma, NSCLC
│       │       ├─ CNS response: 20-30% (melanoma brain mets), less in NSCLC
│       │       └─ Combined with SRS: Synergistic (abscopal effect), ongoing trials
│       └─ HER2+ breast cancer: Trastuzumab-deruxtecan (CNS activity)
│
└─ Prognosis (Graded Prognostic Assessment, GPA) ⭐:
    ├─ Factors: Age, KPS, number of brain metastases, extracranial metastases
    ├─ GPA 0-1: Median survival 3-4 months
    ├─ GPA 1.5-2: Median survival 5-7 months
    ├─ GPA 2.5-3: Median survival 9-11 months
    └─ GPA 3.5-4: Median survival 15-25 months (best prognosis group)

---

## III. CEREBROVASCULAR DISEASE ⭐⭐⭐

### INTRACRANIAL ANEURYSMS ⭐⭐⭐:

├─ Epidemiology:
│   ├─ Prevalence: 3-5% of general population (autopsy/imaging studies)
│   ├─ Rupture incidence: 10 per 100,000 per year (subarachnoid hemorrhage)
│   ├─ Age: Rupture peak 50-60 years
│   └─ Sex: Female:male 3:2 (rupture), hormonal factors
│
├─ Pathophysiology:
│   ├─ Formation:
│   │   ├─ Hemodynamic stress at arterial bifurcations → endothelial injury
│   │   ├─ Loss of internal elastic lamina, medial thinning
│   │   └─ Adventitial outpouching (saccular aneurysm formation)
│   ├─ Growth: 1-2 mm/year (average), accelerates with hypertension, smoking
│   └─ Rupture: Wall tension exceeds strength → SAH
│
├─ Risk factors ⭐⭐:
│   ├─ Modifiable:
│   │   ├─ Hypertension: Most important modifiable risk factor ⭐
│   │   ├─ Smoking: 3-10x increased risk (dose-dependent)
│   │   ├─ Heavy alcohol use: 2-3x increased risk
│   │   └─ Sympathomimetic drugs: Cocaine (acute rupture risk)
│   ├─ Non-modifiable:
│   │   ├─ Family history: First-degree relative with SAH (4x risk, screen if ≥2 relatives)
│   │   ├─ Female sex: 1.5-2x risk
│   │   ├─ Age: Incidence increases with age
│   │   └─ Race: Finnish, Japanese populations (higher prevalence)
│   └─ Associated conditions:
│       ├─ Polycystic kidney disease (ADPKD): 10-15% prevalence (screen with MRA)
│       ├─ Connective tissue disorders: Ehlers-Danlos type IV, Marfan syndrome
│       ├─ Fibromuscular dysplasia (FMD)
│       └─ Moyamoya disease
│
├─ Aneurysm rupture risk factors (PHASES score) ⭐⭐⭐:
│   ├─ Population: North American/European (higher risk) vs Japanese (lower risk)
│   ├─ Hypertension: Present (1 point)
│   ├─ Age: ≥70 years (1 point)
│   ├─ Size ⭐:
│   │   ├─ <7 mm: 0 points (annual rupture risk <0.5%)
│   │   ├─ 7-9.9 mm: 3 points (rupture risk 1-2%/year)
│   │   ├─ 10-19.9 mm: 6 points (rupture risk 2-5%/year)
│   │   └─ ≥20 mm: 10 points (rupture risk 5-10%/year) ⭐
│   ├─ Earlier SAH from another aneurysm: 1 point
│   └─ Site:
│       ├─ AComA, PComA, basilar tip: 2 points (higher rupture risk) ⭐
│       └─ Other locations: 0 points
│   └─ PHASES score interpretation:
│       ├─ 0-2 points: 5-year rupture risk <1%
│       ├─ 3-6 points: 5-year rupture risk 1-5%
│       └─ ≥7 points: 5-year rupture risk >5% (treatment recommended)
│
├─ Unruptured aneurysm management ⭐⭐:
│   ├─ Observation indications:
│   │   ├─ Small (<5-7 mm), low-risk location (MCA, anterior circulation)
│   │   ├─ No prior SAH history
│   │   ├─ Elderly, significant comorbidities
│   │   └─ Patient preference after informed discussion
│   ├─ Surveillance: MRA or CTA every 6-12 months initially, then annually if stable
│   ├─ Growth: 2-5%/year (if grows, treatment recommended)
│   └─ Risk modification: Smoking cessation, blood pressure control, avoid sympathomimetics
│
├─ Ruptured aneurysm (subarachnoid hemorrhage) ⭐⭐⭐:
│   ├─ Clinical presentation:
│   │   ├─ "Worst headache of life": Sudden-onset, thunderclap headache (97%) ⭐
│   │   ├─ Loss of consciousness: 45% (momentary or prolonged)
│   │   ├─ Sentinel headache: Warning leak in 10-40% (days to weeks prior)
│   │   ├─ Meningismus: Neck stiffness, photophobia (develops over hours)
│   │   ├─ Focal neurological deficits: CN III palsy (PComA aneurysm), hemiparesis
│   │   └─ Seizures: 10-25% (at onset or during hospitalization)
│   │
│   ├─ Grading ⭐⭐:
│   │   ├─ Hunt-Hess scale (clinical):
│   │   │   ├─ Grade 1: Asymptomatic or mild headache, slight nuchal rigidity
│   │   │   ├─ Grade 2: Moderate-severe headache, nuchal rigidity, no deficit except CN palsy
│   │   │   ├─ Grade 3: Drowsy, confused, mild focal deficit
│   │   │   ├─ Grade 4: Stupor, moderate-severe hemiparesis
│   │   │   └─ Grade 5: Deep coma, decerebrate posturing, moribund
│   │   ├─ World Federation of Neurosurgical Societies (WFNS):
│   │   │   └─ Based on GCS and focal deficit presence
│   │   └─ Modified Fisher scale (radiographic, vasospasm risk) ⭐:
│   │       ├─ Grade 0: No SAH
│   │       ├─ Grade 1: Thin SAH, no IVH
│   │       ├─ Grade 2: Thin SAH with IVH
│   │       ├─ Grade 3: Thick SAH (>1 mm), no IVH (highest vasospasm risk 70-80%) ⭐
│   │       └─ Grade 4: Thick SAH with IVH
│   │
│   ├─ Diagnostic workup:
│   │   ├─ NCCT head: Subarachnoid blood (sensitivity 95% if <6h, drops to 50% at 1 week)
│   │   ├─ If CT negative but high clinical suspicion: Lumbar puncture ⭐
│   │   │   ├─ Findings: Xanthochromia (yellow CSF), RBC count ≥5/mm³, RBCs not clearing in serial tubes
│   │   │   └─ Timing: Wait 6-12 hours post-headache (allow xanthochromia development)
│   │   ├─ CTA head (after SAH confirmed): Identify aneurysm (sensitivity 95-98% for >3 mm)
│   │   └─ DSA (gold standard):Identify aneurysm, assess morphology, treatment planning
│   │       └─ Four-vessel angiogram if CTA negative (perimesencephalic SAH, rare aneurysm)
│   │
│   ├─ Acute management ⭐⭐⭐:
│   │   ├─ ICU admission (neurocritical care):
│   │   │   ├─ Neuromonitoring: Frequent neurological exams (q1-2h), ICP monitor if poor grade
│   │   │   └─ Blood pressure management ⭐:
│   │   │       ├─ Pre-treatment: SBP <160 mmHg (balance perfusion vs rebleeding risk)
│   │   │       └─ Agents: Nicardipine, labetalol (avoid nitroprusside - ↑ ICP)
│   │   ├─ Nimodipine ⭐⭐⭐:
│   │   │   ├─ Mechanism: Calcium channel blocker (↓ vasospasm, ↓ delayed cerebral ischemia)
│   │   │   ├─ Dose: 60 mg PO q4h for 21 days (start within 96 hours of SAH)
│   │   │   ├─ Benefit: ↓ Poor outcome by 34% (landmark trial) ⭐
│   │   │   └─ Side effects: Hypotension (dose adjust if SBP <100), hold if cannot tolerate
│   │   ├─ Seizure prophylaxis:
│   │   │   ├─ Levetiracetam 500-1000 mg q12h (short-term, 3-7 days)
│   │   │   └─ Avoid phenytoin (worse neurological outcomes in some studies)
│   │   ├─ Hydrocephalus management:
│   │   │   ├─ Acute hydrocephalus: 20-30% (IVH, cisternal blood obstructs CSF flow)
│   │   │   ├─ EVD placement: Indications = declining GCS, symptomatic hydrocephalus
│   │   │   └─ Chronic hydrocephalus: 10-20% (requires VP shunt placement)
│   │   └─ Rebleeding prevention:
│   │       ├─ Rebleeding risk: 4% in first 24h, then 1-2%/day (cumulative 20% at 2 weeks) ⭐
│   │       └─ Definitive treatment: Within 24-72 hours (early aneurysm securing)
│   │
│   ├─ Definitive treatment ⭐⭐⭐:
│   │   ├─ Endovascular coiling ⭐⭐⭐:
│   │   │   ├─ Technique: Detachable platinum coils via microcatheter, pack aneurysm
│   │   │   ├─ Indications (preferred for):
│   │   │   │   ├─ Posterior circulation aneurysms (basilar, PICA)
│   │   │   │   ├─ Poor surgical candidates (elderly, poor grade)
│   │   │   │   ├─ Wide-necked aneurysms: Stent or balloon-assisted coiling
│   │   │   │   └─ Giant aneurysms: Flow diversion (Pipeline device)
│   │   │   ├─ ISAT trial (2002, landmark) ⭐⭐:
│   │   │   │   ├─ Coiling vs clipping (ruptured aneurysms suitable for both)
│   │   │   │   ├─ Death/dependence at 1 year: 23.7% (coiling) vs 30.6% (clipping) ⭐
│   │   │   │   ├─ Rebleeding: Slightly higher with coiling (rare, <1%/year)
│   │   │   │   └─ Conclusion: Coiling preferred if anatomically suitable
│   │   │   ├─ Complications:
│   │   │   │   ├─ Thromboembolic stroke: 5-10% (embolic during procedure)
│   │   │   │   ├─ Aneurysm perforation: 2-5% (higher mortality if ruptured)
│   │   │   │   └─ Recurrence/recanalization: 20-30% (requires follow-up imaging, retreatment 10-15%)
│   │   │   └─ Follow-up: CTA or MRA at 6 months, 1 year, then periodically
│   │   │
│   │   └─ Microsurgical clipping ⭐⭐:
│   │       ├─ Technique: Craniotomy, clip across aneurysm neck (excluding from circulation)
│   │       ├─ Indications (preferred for):
│   │       │   ├─ MCA bifurcation aneurysms (surgical access easier)
│   │       │   ├─ Broad-necked anterior circulation aneurysms (unfavorable coiling geometry)
│   │       │   ├─ Young patients (durable, avoids long-term coil recurrence risk)
│   │       │   └─ Associated ICH requiring evacuation
│   │       ├─ Approach by location:
│   │       │   ├─ AComA, PComA, MCA: Pterional craniotomy
│   │       │   ├─ Basilar tip: Subtemporal, orbitozygomatic, or transpetrosal approach
│   │       │   └─ PICA: Lateral suboccipital craniotomy
│   │       ├─ Intraoperative adjuncts:
│   │       │   ├─ ICG angiography: Confirm clip placement, parent vessel patency ⭐
│   │       │   ├─ Temporary clipping: Proximal control during dissection (limit <15 min)
│   │       │   └─ Neuromonitoring: SSEPs, MEPs (detect ischemia)
│   │       ├─ Complications:
│   │       │   ├─ Ischemic stroke: 5-10% (perforator injury, parent vessel stenosis)
│   │       │   ├─ Intraoperative rupture: 5-10% (controlled with temporary clipping)
│   │       │   ├─ Incomplete clipping: 2-5% (residual neck, requires post-op DSA)
│   │       │   └─ Cranial nerve injury: <5% (CN II, III with PComA/AComA)
│   │       └─ Outcomes:
│   │           ├─ Complete occlusion: 90-95% (durable, low retreatment rate)
│   │           └─ Mortality: 1-2% (elective), higher in poor-grade SAH
│   │
│   ├─ Complications of SAH ⭐⭐⭐:
│   │   ├─ Delayed cerebral ischemia (DCI, "vasospasm") ⭐⭐⭐:
│   │   │   ├─ Incidence: 20-40% (clinical DCI, new deficit)
│   │   │   ├─ Timing: Peak 5-14 days post-SAH (mean day 7) ⭐
│   │   │   ├─ Risk factors: Modified Fisher grade 3-4 (thick blood), poor clinical grade
│   │   │   ├─ Monitoring:
│   │   │   │   ├─ Clinical: Frequent neuro exams (decline in GCS, new focal deficit)
│   │   │   │   ├─ Transcranial Doppler (TCD): Daily, mean velocity >120 cm/s (MCA), Lindegaard ratio >3
│   │   │   │   └─ CTA/DSA: If clinical decline (confirm vasospasm, guide treatment)
│   │   │   ├─ Prevention:
│   │   │   │   ├─ Nimodipine: 60 mg PO q4h x 21 days (MANDATORY) ⭐
│   │   │   │   ├─ Euvolemia: Maintain normovolemia (avoid hypo- and hypervolemia)
│   │   │   │   └─ Blood pressure: Allow permissive hypertension after aneurysm secured (SBP 160-180)
│   │   │   └─ Treatment (if DCI occurs):
│   │   │       ├─ Induced hypertension: SBP 180-220 mmHg (↑ cerebral perfusion pressure)
│   │   │       ├─ Endovascular therapy:
│   │   │       │   ├─ Intra-arterial vasodilators: Verapamil, nicardipine (direct infusion)
│   │   │       │   └─ Angioplasty: Mechanical dilation (proximal large vessel vasospasm)
│   │   │       └─ Outcomes: DCI contributes to 10-15% mortality, 10-20% permanent deficit
│   │   ├─ Hydrocephalus (see above)
│   │   ├─ Seizures: 10-25% (managed with levetiracetam)
│   │   └─ Medical complications:
│   │       ├─ Cardiac: Takotsubo cardiomyopathy (stress-induced), arrhythmias, myocardial ischemia (20-30%)
│   │       ├─ Pulmonary: Neurogenic pulmonary edema (5-10%), aspiration pneumonia
│   │       ├─ Hyponatremia: SIADH, cerebral salt wasting (20-40%, treat with hypertonic saline)
│   │       └─ Venous thromboembolism: DVT/PE (prophylaxis with SCDs, heparin after aneurysm secured)
│   │
│   └─ Prognosis ⭐⭐:
│       ├─ Mortality: 25-50% overall (12% die before reaching hospital, 25% die within 24h)
│       ├─ Good recovery (modified Rankin Scale 0-2): 50-60% (good-grade SAH), 20-30% (poor-grade)
│       ├─ Predictors of poor outcome:
│       │   ├─ Poor clinical grade (Hunt-Hess 4-5, WFNS 4-5)
│       │   ├─ Older age (>70 years)
│       │   ├─ Thick SAH (modified Fisher 3-4)
│       │   ├─ Delayed cerebral ischemia
│       │   └─ Medical complications
│       └─ Long-term: Cognitive impairment (40-50%), depression, epilepsy (5-10% develop)

### CAVERNOUS MALFORMATIONS (CAVERNOMAS) ⭐⭐:

├─ Epidemiology:
│   ├─ Prevalence: 0.4-0.8% of population (MRI studies)
│   ├─ Familial: 20% (autosomal dominant, multiple lesions)
│   └─ Age: Any age, symptomatic presentation peak 20-40 years
│
├─ Molecular genetics (familial cavernous malformation) ⭐:
│   ├─ Genes (loss of function mutations):
│   │   ├─ CCM1 (KRIT1): 40% of familial cases
│   │   ├─ CCM2 (malcavernin): 20%
│   │   └─ CCM3 (PDCD10): 10-15%
│   ├─ Inheritance: Autosomal dominant with incomplete penetrance (80-90%)
│   └─ De novo somatic mutations: Sporadic cases (two-hit hypothesis)
│
├─ Pathology:
│   ├─ Structure: Clustered, dilated capillary channels ("mulberry" appearance) ⭐
│   ├─ No intervening brain tissue (unlike AVM)
│   ├─ Hemosiderin deposition: From recurrent microhemorrhages
│   └─ Gliosis: Surrounding reactive gliosis
│
├─ Clinical presentation:
│   ├─ Seizures: 40-60% (most common, especially cortical lesions) ⭐
│   ├─ Hemorrhage: 25-35% (symptomatic bleed)
│   │   ├─ Annual bleed risk: 0.25-3%/year (varies by location, presentation)
│   │   ├─ Prior hemorrhage: ↑ rebleed risk 5%/year
│   │   └─ Brainstem/deep lesions: Higher symptomatic bleed risk
│   ├─ Focal neurological deficits: 20-40% (mass effect, prior hemorrhage)
│   └─ Asymptomatic: 30-40% (incidental finding)
│
├─ Imaging ⭐⭐:
│   ├─ MRI (diagnostic):
│   │   ├─ T1: Variable signal (blood products of different ages)
│   │   ├─ T2: "Popcorn" appearance (mixed signal core) ⭐
│   │   ├─ GRE/SWI ⭐⭐:
│   │   │   ├─ "Blooming" dark hemosiderin rim (pathognomonic) ⭐
│   │   │   └─ Multiple developmental venous anomalies (DVAs) in 10-30%
│   │   └─ No contrast enhancement (angiographically occult)
│   ├─ CT: Often isodense, calcification (10-30%)
│   └─ DSA: Angiographically occult ("cryptic" vascular malformation)
│
├─ Treatment ⭐⭐:
│   ├─ Observation:
│   │   ├─ Indications: Asymptomatic, deep/eloquent location, low bleed risk
│   │   └─ Surveillance: MRI every 1-2 years (assess growth, new hemorrhage)
│   ├─ Surgery (microsurgical resection):
│   │   ├─ Indications:
│   │   │   ├─ Refractory seizures despite medical management ⭐
│   │   │   ├─ Symptomatic hemorrhage (especially if superficial/accessible)
│   │   │   ├─ Progressive neurological deficit
│   │   │   └─ Superficial/non-eloquent location (favorable surgical risk)
│   │   ├─ Technique: En bloc resection with hemosiderin rim (reduces seizure recurrence)
│   │   ├─ Outcomes:
│   │   │   ├─ Seizure freedom: 70-85% (if complete resection + hemosiderin removal)
│   │   │   ├─ Hemorrhage prevention: 100% (if complete resection)
│   │   │   └─ Surgical morbidity: 5-15% (depends on location)
│   │   └─ Brainstem cavernomas: High surgical risk (defer unless recurrent bleeds)
│   ├─ Stereotactic radiosurgery (SRS):
│   │   ├─ Indications: Deep/eloquent (brainstem), surgery high-risk, recurrent hemorrhage
│   │   ├─ Dose: 12-18 Gy (margin)
│   │   ├─ Mechanism: Endothelial obliteration, fibrosis (takes 2-3 years)
│   │   ├─ Hemorrhage reduction: Conflicting data, may reduce bleeding over time
│   │   └─ Complications: Radiation necrosis (rare), does NOT prevent early rebleeding
│   └─ Antiepileptic drugs: For seizure control (levetiracetam, lacosamide)
│
└─ Prognosis:
    ├─ Natural history: Benign if asymptomatic, slow growth
    ├─ Hemorrhage: Usually self-limited (small bleeds), rarely catastrophic
    └─ Surgical outcomes: Excellent if superficial/accessible, seizure freedom high

---

## IV. DEGENERATIVE SPINE DISEASE ⭐⭐⭐

### LUMBAR DISC HERNIATION ⭐⭐⭐:

├─ Epidemiology:
│   ├─ Prevalence: 2-3% of population (symptomatic)
│   ├─ Incidence: 5 per 1,000 adults per year
│   ├─ Age: Peak 30-50 years (nucleus pulposus still gelatinous)
│   ├─ Sex: Male:female 2:1
│   └─ Level: L4-L5 (45-50%), L5-S1 (40-45%), L3-L4 (5-10%) ⭐
│
├─ Pathophysiology:
│   ├─ Disc degeneration: Loss of proteoglycans → desiccation, ↓ disc height
│   ├─ Annular tear: Radial tear in annulus fibrosus (posterior/posterolateral) ⭐
│   ├─ Nucleus herniation: Nucleus pulposus extrudes through tear
│   └─ Nerve root compression: Direct compression + inflammatory mediators (PLA2, TNF-α, IL-1)
│
├─ Clinical presentation ⭐⭐⭐:
│   ├─ Radiculopathy (sciatic) ⭐⭐:
│   │   ├─ Dermatomal pain: Sharp, shooting pain down leg (follows dermatome)
│   │   ├─ Motor weakness (specific to nerve root):
│   │   │   ├─ L3: Knee extension (quadriceps), patellar reflex ↓
│   │   │   ├─ L4: Ankle dorsiflexion, tibialis anterior
│   │   │   ├─ L5: Great toe extension (EHL), ankle dorsiflexion ⭐
│   │   │   └─ S1: Plantar flexion (gastrocnemius), Achilles reflex ↓ ⭐
│   │   ├─ Sensory deficits:
│   │   │   ├─ L4: Medial leg and foot
│   │   │   ├─ L5: Dorsum of foot, first web space ⭐
│   │   │   └─ S1: Lateral foot, sole
│   │   └─ Reflexes:
│   │       ├─ L3-L4: Patellar (knee jerk) ↓
│   │       └─ S1: Achilles (ankle jerk) ↓
│   ├─ Back pain: 90% (axial low back pain, worse with flexion/Valsalva)
│   ├─ Positive straight leg raise (SLR) ⭐:
│   │   ├─ Technique: Passive leg elevation (hip flexion, knee extended)
│   │   ├─ Positive: Radicular pain <60-70 degrees (high sensitivity 90%, low specificity)
│   │   └─ Crossed SLR: Contralateral leg raise reproduces pain (high specificity for herniation)
│   └─ Cauda equina syndrome (rare, surgical emergency) ⭐⭐⭐:
│       ├─ Central massive disc herniation compressing cauda equina
│       ├─ Clinical features:
│       │   ├─ Saddle anesthesia (perianal, perineal numbness) ⭐
│       │   ├─ Bowel/bladder dysfunction (urinary retention > incontinence initially)
│       │   ├─ Bilateral leg weakness/numbness
│       │   └─ Sexual dysfunction (erectile dysfunction, loss of sensation)
│       └─ Management: EMERGENCY surgery (decompression within 24-48h to preserve function)
│
├─ Diagnostic workup:
│   ├─ MRI lumbar spine (preferred imaging) ⭐:
│   │   ├─ T2 sagittal: Disc desiccation (dark), herniation, canal stenosis
│   │   ├─ T2 axial: Neural foraminal stenosis, nerve root compression ⭐
│   │   └─ Classification: Protrusion (base > apex), extrusion (base < apex), sequestration (free fragment)
│   ├─ CT lumbar spine: Alternative if MRI contraindicated (less soft tissue detail)
│   └─ Electromyography (EMG/NCS): If diagnosis uncertain, rule out peripheral neuropathy
│
├─ Treatment ⭐⭐⭐:
│   ├─ Conservative management (FIRST-LINE, 80-90% improve) ⭐⭐:
│   │   ├─ Natural history: 70-90% spontaneous improvement in 6-12 weeks
│   │   ├─ NSAIDs: Ibuprofen, naproxen (anti-inflammatory + analgesic)
│   │   ├─ Neuropathic pain agents: Gabapentin, pregabalin (radicular pain)
│   │   ├─ Muscle relaxants: Cyclobenzaprine, tizanidine (short-term, <2 weeks)
│   │   ├─ Physical therapy: After acute phase (avoid bed rest >2 days)
│   │   ├─ Epidural steroid injection (ESI):
│   │   │   ├─ Transforaminal ESI: Fluoroscopy-guided, targets specific nerve root ⭐
│   │   │   ├─ Efficacy: 50-70% short-term relief (weeks to months), less effective long-term
│   │   │   └─ Indications: Refractory pain, surgical candidate unwilling/unable to undergo surgery
│   │   └─ Duration: Conservative trial 6-12 weeks (if no progressive motor weakness)
│   │
│   ├─ Surgery (microdiscectomy) ⭐⭐⭐:
│   │   ├─ Indications:
│   │   │   ├─ ABSOLUTE:
│   │   │   │   └─ Cauda equina syndrome (EMERGENCY within 24-48h) ⭐⭐
│   │   │   ├─ RELATIVE:
│   │   │   │   ├─ Progressive motor weakness (foot drop, significant weakness) ⭐
│   │   │   │   ├─ Severe, disabling pain refractory to 6-12 weeks conservative management
│   │   │   │   ├─ Recurrent debilitating pain episodes
│   │   │   │   └─ Patient preference (expedite recovery, return to work)
│   │   ├─ Technique:
│   │   │   ├─ Approach: Posterior midline or paramedian incision, laminotomy (not laminectomy)
│   │   │   ├─ Dissection: Retract paraspinal muscles, identify lamina/ligamentum flavum
│   │   │   ├─ Decompression: Remove ligamentum flavum, retract nerve root, identify disc fragment
│   │   │   ├─ Discectomy: Remove extruded fragment + loose disc material (avoid aggressive discectomy)
│   │   │   └─ Minimally invasive: Tubular retractors, endoscopic (faster recovery, less tissue trauma)
│   │   ├─ Outcomes (SPORT trial, Surgery vs Conservative management) ⭐⭐:
│   │   │   ├─ Short-term (3-6 months): Surgery superior pain relief, functional improvement
│   │   │   ├─ Long-term (2-4 years): Benefit diminishes, both groups improve (crossover 30%)
│   │   │   ├─ Leg pain relief: 80-90% excellent/good at 1 year (surgery)
│   │   │   └─ Patient satisfaction: 85-95% satisfied
│   │   ├─ Complications:
│   │   │   ├─ Dural tear (CSF leak): 3-10% (repair primarily, rarely requires reoperation)
│   │   │   ├─ Nerve root injury: 1-2% (transient weakness, dysesthesias)
│   │   │   ├─ Infection (discitis): 1-2%
│   │   │   ├─ Recurrent disc herniation: 5-10% (same level, same side) ⭐
│   │   │   │   └─ Risk factors: Young age, smoking, traumatic event
│   │   │   └─ Wrong-level surgery: <1% (prevented by intraoperative X-ray/fluoroscopy)
│   │   └─ Rehabilitation: Mobilize same day, return to light activity 2-4 weeks, full 6-12 weeks
│   │
│   └─ Fusion (not indicated for simple disc herniation):
│       └─ Only if coexistent instability (spondylolisthesis, severe degenerative changes)
│
└─ Prognosis:
    ├─ Conservative: 70-90% improve in 6-12 weeks
    ├─ Surgical: 85-95% good/excellent outcomes, faster recovery than conservative
    └─ Recurrence: 5-10% (lower with limited discectomy, avoid aggressive disc removal)

---

### LUMBAR SPINAL STENOSIS ⭐⭐⭐:

├─ Epidemiology:
│   ├─ Prevalence: 10% of population >50 years, 30% >60 years
│   ├─ Age: Peak >65 years (degenerative etiology)
│   └─ Sex: Male = female
│
├─ Pathophysiology ⭐⭐:
│   ├─ Degenerative cascade:
│   │   ├─ Disc degeneration → ↓ disc height → ↑ facet joint load
│   │   ├─ Facet arthropathy: Hypertrophy, osteophyte formation
│   │   ├─ Ligamentum flavum hypertrophy (buckling into canal) ⭐
│   │   └─ Result: Central canal stenosis, lateral recess stenosis, foraminal stenosis
│   └─ Congenital stenosis: Narrow canal (<10 mm AP diameter), symptoms earlier
│
├─ Clinical presentation ⭐⭐⭐:
│   ├─ Neurogenic claudication ⭐⭐⭐:
│   │   ├─ Bilateral leg pain, heaviness, fatigue with ambulation
│   │   ├─ Distance-dependent: Reproducible walking distance before symptoms
│   │   ├─ Relieved by: Sitting, forward flexion (↑ canal diameter) ⭐
│   │   │   └─ "Shopping cart sign": Leaning forward on cart relieves symptoms
│   │   └─ Worsened by: Standing upright, extension (↓ canal diameter)
│   ├─ Back pain: 95% (chronic axial low back pain)
│   ├─ Radiculopathy: May coexist (foraminal stenosis)
│   └─ Differentiate from vascular claudication:
│       ├─ Vascular: Relieved by standing still (reperfusion), absent pulses, skin changes
│       └─ Neurogenic: Must sit or flex spine, normal pulses, no skin changes ⭐
│
├─ Imaging:
│   ├─ MRI lumbar spine ⭐:
│   │   ├─ T2 sagittal: Central canal narrowing, ligamentum flavum hypertrophy (dark)
│   │   ├─ T2 axial: "Trefoil" canal shape, nerve root crowding, CSF effacement
│   │   └─ Severity: AP diameter <10 mm (severe), 10-13 mm (moderate)
│   ├─ CT: Bony detail, foraminal stenosis assessment
│   └─ Standing X-rays: Dynamic instability (spondylolisthesis, degenerative scoliosis)
│
├─ Treatment ⭐⭐⭐:
│   ├─ Conservative (FIRST-LINE):
│   │   ├─ NSAIDs, activity modification, weight loss
│   │   ├─ Physical therapy: Core strengthening, flexion exercises (McKenzie protocol)
│   │   ├─ Epidural steroid injections: 30-50% short-term relief (less effective than for disc herniation)
│   │   └─ Duration: 3-6 months trial (symptoms often progressive over time)
│   │
│   ├─ Surgery (decompression ± fusion) ⭐⭐⭐:
│   │   ├─ Indications:
│   │   │   ├─ Severe symptoms limiting quality of life (neurogenic claudication)
│   │   │   ├─ Failed conservative management (3-6 months)
│   │   │   ├─ Progressive neurological deficit (rare in stenosis)
│   │   │   └─ Radiographic stenosis correlating with symptoms
│   │   ├─ Decompression alone (laminectomy) ⭐⭐:
│   │   │   ├─ Technique: Remove lamina, ligamentum flavum, decompress nerve roots (bilateral)
│   │   │   ├─ Preserve facets: >50% facet preservation (avoid iatrogenic instability) ⭐
│   │   │   ├─ Outcomes (SPORT stenosis trial):
│   │   │   │   ├─ Surgery: Significant improvement in pain, function (2-4 years)
│   │   │   │   ├─ Conservative: Some improvement, slower and less complete
│   │   │   │   └─ Crossover: 40% conservative group eventually had surgery
│   │   │   ├─ Satisfaction: 70-85% satisfied with surgery
│   │   │   └─ Complications: Dural tear (10-15%), infection (2-4%), progression (adjacent segment)
│   │   │
│   │   └─ Fusion (added to decompression) ⭐:
│   │       ├─ Indications:
│   │       │   ├─ Degenerative spondylolisthesis (>3-4 mm slip) ⭐
│   │       │   ├─ Degenerative scoliosis (>10-15 degrees)
│   │       │   ├─ Iatrogenic instability (>50% facet resection required for decompression)
│   │       │   └─ Recurrent stenosis after prior decompression
│   │       ├─ Technique: Pedicle screw-rod instrumentation + interbody/posterolateral fusion
│   │       ├─ Outcomes:
│   │       │   ├─ Decompression + fusion vs decompression alone (with spondylolisthesis):
│   │       │   │   └─ Fusion superior outcomes (lower reoperation rate, better stability) ⭐
│   │       │   └─ Fusion rate: 85-95% (with instrumentation + bone graft)
│   │       └─ Complications: Higher than decompression alone (hardware, pseudarthrosis 5-10%, adjacent segment disease)
│   │
│   └─ Interspinous spacers (mild stenosis):
│       ├─ Device: Spacer between spinous processes (maintains flexed position)
│       └─ Limited efficacy, high removal rate (not widely adopted)
│
└─ Prognosis:
    ├─ Natural history: Slowly progressive (not all patients worsen)
    ├─ Surgical: 70-85% good/excellent outcomes, durable improvement
    └─ Adjacent segment disease: 10-15% over 10 years (if fusion performed)

---

## V. TRAUMATIC BRAIN INJURY ⭐⭐⭐

### SEVERE TRAUMATIC BRAIN INJURY (GCS ≤8) ⭐⭐⭐:

├─ Epidemiology:
│   ├─ Incidence: 50-60 per 100,000 (severe TBI requiring hospitalization)
│   ├─ Age: Bimodal (15-24 years, >75 years)
│   ├─ Sex: Male:female 2-3:1
│   ├─ Mechanisms: MVC (50%), falls (30%), assault (10%), penetrating (10%)
│   └─ Mortality: 30-40% (severe TBI)
│
├─ Pathophysiology ⭐⭐:
│   ├─ Primary injury:
│   │   ├─ Direct mechanical trauma: Contusion, laceration, hematoma, DAI
│   │   └─ Occurs at moment of impact (not preventable after injury)
│   └─ Secondary injury ⭐⭐⭐:
│       ├─ Intracranial mechanisms:
│       │   ├─ Cerebral edema: Cytotoxic (cellular swelling), vasogenic (BBB breakdown)
│       │   ├─ ↑ Intracranial pressure (ICP): Mass lesions, edema, hydrocephalus
│       │   ├─ ↓ Cerebral perfusion pressure (CPP = MAP - ICP): Goal CPP 60-70 mmHg ⭐
│       │   ├─ Excitotoxicity: Glutamate release, calcium influx, neuronal death
│       │   └─ Inflammation: Microglial activation, cytokine release
│       └─ Systemic mechanisms:
│           ├─ Hypotension: Single episode (SBP <90 mmHg) → ↑ mortality by 50% ⭐
│           ├─ Hypoxia: SpO2 <90% → ↑ mortality, worse outcomes
│           ├─ Hyperglycemia: >180 mg/dL associated with worse outcomes
│           └─ Hyperthermia: Fever (>38.5°C) → ↑ metabolic demand, worse outcomes
│
├─ Initial management (trauma bay, prehospital) ⭐⭐⭐:
│   ├─ ABCs (ATLS protocol):
│   │   ├─ Airway: Secure airway if GCS ≤8 (endotracheal intubation) ⭐
│   │   ├─ Breathing: Maintain SpO2 >94%, avoid hyperventilation (except acute herniation)
│   │   ├─ Circulation: Maintain SBP ≥110 mmHg (age 50-69), ≥100 mmHg (15-49, >70) ⭐
│   │   │   └─ Fluid resuscitation: Isotonic crystalloid (avoid hypotonic fluids)
│   │   └─ Cervical spine: Immobilization until cleared (CT C-spine, MRI if needed)
│   ├─ Imaging (NCCT head):
│   │   ├─ Identify: Hematoma (EDH, SDH, IPH), contusions, SAH, fractures, midline shift
│   │   └─ Surgical lesions: EDH >30 cc, SDH >10 mm or shift >5 mm
│   ├─ Neurosurgical consultation: If GCS ≤8, surgical lesion, deterioration
│   └─ Avoid secondary insults: Prevent hypotension, hypoxia, hyperthermia
│
├─ Neurocritical care management ⭐⭐⭐:
│   ├─ ICP monitoring ⭐⭐:
│   │   ├─ Indications (Brain Trauma Foundation guidelines):
│   │   │   ├─ GCS ≤8 with abnormal CT (hematoma, contusion, edema, shift, cistern compression)
│   │   │   ├─ GCS ≤8 with normal CT + ≥2 of: Age >40, SBP <90, posturing
│   │   │   └─ Post-craniotomy if at risk for edema/swelling
│   │   ├─ Device: External ventricular drain (EVD, most accurate + therapeutic) or intraparenchymal (Codman, Camino)
│   │   ├─ Target: ICP <22 mmHg ⭐
│   │   └─ CPP goal: 60-70 mmHg (CPP = MAP - ICP)
│   │
│   ├─ Tier 1 interventions (first-line) ⭐⭐:
│   │   ├─ Head of bed elevation: 30-45 degrees (↑ venous drainage)
│   │   ├─ Sedation/analgesia: Propofol (caution with prolonged use), fentanyl (avoid BP drop)
│   │   ├─ Osmotic therapy ⭐⭐:
│   │   │   ├─ Mannitol (20%):
│   │   │   │   ├─ Dose: 0.25-1 g/kg IV bolus (repeat PRN, maintain serum osm <320 mOsm/L)
│   │   │   │   ├─ Mechanism: ↓ ICP via osmotic gradient, ↓ blood viscosity (↑ CBF, vasoconstriction)
│   │   │   │   └─ Monitor: Serum osmolality, electrolytes, renal function
│   │   │   └─ Hypertonic saline (3%, 23.4%):
│   │   │       ├─ Dose: 3% continuous infusion or 23.4% bolus (30 mL)
│   │   │       ├─ Target: Serum sodium 145-155 mEq/L
│   │   │       └─ Advantage: Volume expansion (vs mannitol diuresis), no renal toxicity
│   │   ├─ CSF drainage: If EVD in place, open to drainage (intermittent or continuous)
│   │   ├─ Avoid hyperthermia: Acetaminophen, cooling devices (target <38°C)
│   │   └─ Seizure prophylaxis: Levetiracetam 500-1000 mg q12h x 7 days (prevent early seizures)
│   │
│   ├─ Tier 2 interventions (refractory ICP) ⭐:
│   │   ├─ Moderate hyperventilation:
│   │   │   ├─ Target: PaCO2 30-35 mmHg (temporary measure, <24h)
│   │   │   ├─ Mechanism: Vasoconstriction → ↓ CBV → ↓ ICP
│   │   │   └─ Caution: Cerebral ischemia if excessive (PaCO2 <30), monitor SjvO2 or PbtO2
│   │   ├─ Barbiturate coma (pentobarbital) ⭐:
│   │   │   ├─ Indications: Refractory ICP despite maximal medical management
│   │   │   ├─ Dose: 10 mg/kg loading, then 1-4 mg/kg/h (titrate to burst suppression on EEG)
│   │   │   ├─ Mechanism: ↓ Cerebral metabolic rate → ↓ CBF → ↓ ICP
│   │   │   ├─ Monitoring: Continuous EEG (burst suppression), ICP, hemodynamics
│   │   │   └─ Side effects: Hypotension (requires vasopressors), immunosuppression, ileus
│   │   └─ Decompressive craniectomy ⭐⭐:
│   │       ├─ DECRA trial (prophylactic, diffuse injury):
│   │       │   └─ Early bifrontal craniectomy → worse outcomes (more vegetative state) ⭐
│   │       ├─ RESCUEicp trial (refractory ICP) ⭐⭐:
│   │       │   ├─ Decompressive craniectomy vs medical management (ICP >25 mmHg refractory)
│   │       │   ├─ Results: ↓ mortality (27% vs 49%), ↑ survival with severe disability
│   │       │   └─ Conclusion: Reduces mortality but increases severe disability
│   │       ├─ Technique: Large hemicraniectomy (≥12 cm diameter), duraplasty (augment dural expansion)
│   │       └─ Complications: Infection (5-10%), hygroma, seizures, "syndrome of the trephined"
│   │
│   └─ Multimodal neuromonitoring:
│       ├─ Brain tissue oxygenation (PbtO2): Goal >20 mmHg (ischemia <15 mmHg)
│       ├─ Jugular venous oximetry (SjvO2): Goal 55-75% (cerebral oxygen extraction)
│       └─ Microdialysis: Lactate/pyruvate ratio (metabolic crisis), glucose (ischemia)
│
├─ Surgical indications (mass lesions) ⭐⭐:
│   ├─ Epidural hematoma:
│   │   ├─ Evacuation if: Volume >30 cc OR GCS ≤8 OR anisocoria OR midline shift >5 mm ⭐
│   │   └─ Observation: Small (<30 cc), no shift, GCS 15, close monitoring
│   ├─ Subdural hematoma:
│   │   ├─ Evacuation if: Thickness >10 mm OR midline shift >5 mm ⭐
│   │   ├─ Also evacuate if: GCS decline ≥2 points, pupillary changes, ICP >20 mmHg
│   │   └─ Technique: Large craniotomy (not burr holes for acute SDH)
│   └─ Intraparenchymal contusion:
│       ├─ Evacuation if: Progressive neurological decline, mass effect, ICP elevation
│       └─ Observation: Stable, no mass effect (contusions may expand in first 24-48h)
│
└─ Prognosis ⭐⭐:
    ├─ Mortality: 30-40% (severe TBI, GCS ≤8)
    ├─ Outcomes (Glasgow Outcome Scale Extended, GOSE):
    │   ├─ Good recovery (GOSE 7-8): 20-30%
    │   ├─ Moderate disability (GOSE 5-6): 15-25%
    │   ├─ Severe disability (GOSE 3-4): 15-20%
    │   ├─ Vegetative state (GOSE 2): 5-10%
    │   └─ Death (GOSE 1): 30-40%
    └─ Prognostic factors:
        ├─ Favorable: Younger age, higher GCS, reactive pupils, no hypotension/hypoxia
        └─ Unfavorable: Age >60, GCS 3-4, fixed pupils, hypotension, mass lesion

---

## VI. HYDROCEPHALUS ⭐⭐⭐

### HYDROCEPHALUS CLASSIFICATION AND TREATMENT ⭐⭐⭐:

├─ Definition: Abnormal accumulation of CSF → ventricular enlargement
│
├─ Classification ⭐⭐:
│   ├─ Obstructive (non-communicating):
│   │   ├─ Obstruction within ventricular system (before subarachnoid space)
│   │   ├─ Sites: Foramen of Monro, aqueduct of Sylvius ⭐ (most common), 4th ventricle outlets
│   │   └─ Causes: Tumor (colloid cyst, tectal glioma, pineal), aqueductal stenosis, post-hemorrhagic
│   └─ Communicating:
│       ├─ Impaired CSF absorption (arachnoid granulations) or overproduction
│       ├─ Causes: Post-SAH/IVH, post-meningitis, normal pressure hydrocephalus (NPH)
│       └─ All ventricles enlarged (vs proximal dilation in obstructive)
│
├─ Normal pressure hydrocephalus (NPH) ⭐⭐⭐:
│   ├─ Epidemiology:
│   │   ├─ Prevalence: 1-2% of population >65 years
│   │   └─ Etiology: Idiopathic (70%), secondary (post-SAH, trauma, meningitis, 30%)
│   ├─ Pathophysiology:
│   │   ├─ Impaired CSF absorption at arachnoid granulations
│   │   ├─ Normal opening pressure on LP (10-18 cmH2O, but pulsatile ↑ at night)
│   │   └─ Ventriculomegaly out of proportion to atrophy ⭐
│   ├─ Clinical presentation (Hakim triad) ⭐⭐⭐:
│   │   ├─ Gait disturbance (earliest, most common 90%) ⭐:
│   │   │   ├─ "Magnetic" gait: Shuffling, broad-based, feet "stuck" to floor
│   │   │   ├─ Difficulty initiating gait, turning
│   │   │   └─ Improves with shunting: Best predictor of shunt responsiveness
│   │   ├─ Cognitive impairment (75%):
│   │   │   ├─ Subcortical dementia: Psychomotor slowing, executive dysfunction
│   │   │   ├─ Memory: Retrieval deficits (vs encoding deficits in Alzheimer's)
│   │   │   └─ Partially reversible with shunting
│   │   └─ Urinary incontinence (60%):
│   │       ├─ Urinary urgency, frequency → incontinence
│   │       └─ Late finding (gait and cognition precede)
│   ├─ Diagnostic workup ⭐⭐:
│   │   ├─ MRI brain:
│   │   │   ├─ Ventriculomegaly: Evans index >0.3 (frontal horn width / skull width) ⭐
│   │   │   ├─ Disproportionately enlarged subarachnoid space hydrocephalus (DESH): Tight high convexity sulci
│   │   │   ├─ Flow void sign: CSF flow through aqueduct (T2)
│   │   │   └─ Periventricular T2 hyperintensity: Transependymal CSF flow
│   │   ├─ Shunt responsiveness testing:
│   │   │   ├─ High-volume LP (tap test) ⭐:
│   │   │   │   ├─ Remove 30-50 mL CSF via LP
│   │   │   │   ├─ Assess gait before and 2-4 hours after (timed up-and-go test)
│   │   │   │   ├─ Improvement: Positive predictive value 80-90% (shunt will help) ⭐
│   │   │   │   └─ No improvement: Does NOT exclude shunt benefit (NPV 50-60%)
│   │   │   ├─ External lumbar drainage (ELD):
│   │   │   │   ├─ Continuous CSF drainage (10-20 mL/h) for 3-5 days
│   │   │   │   ├─ More sensitive than tap test (86% sensitivity)
│   │   │   │   └─ Complications: Infection (5%), CSF leak
│   │   │   └─ CSF outflow resistance (Rout):
│   │   │       └─ Rout >12-18 mmHg/mL/min: Impaired absorption (supports shunting)
│   │   └─ Exclude other causes: Alzheimer's disease (PET amyloid scan), Parkinson's (no tremor in NPH)
│   ├─ Treatment (VP shunt) ⭐⭐⭐:
│   │   ├─ Indications: Probable/possible NPH with positive tap test or clinical trial of shunting
│   │   ├─ Shunt system:
│   │   │   ├─ Ventricular catheter: Frontal (Kocher's point) or parietal (Frazier's point)
│   │   │   ├─ Valve: Programmable valve (can adjust pressure non-invasively) ⭐
│   │   │   │   └─ Settings: Medium pressure (10-15 cmH2O) initially, adjust based on response
│   │   │   └─ Distal catheter: Peritoneal cavity (VP shunt, most common)
│   │   ├─ Outcomes ⭐:
│   │   │   ├─ Gait improvement: 60-90% (most responsive symptom) ⭐
│   │   │   ├─ Cognitive improvement: 40-70% (modest, prevents further decline)
│   │   │   ├─ Urinary improvement: 50-80%
│   │   │   └─ Sustained benefit: 50-70% at 2-5 years
│   │   ├─ Complications ⭐:
│   │   │   ├─ Infection (shunt infection): 5-10% (Staph epidermidis, Staph aureus)
│   │   │   │   └─ Treatment: Shunt removal + EVD, IV antibiotics, new shunt after CSF sterile
│   │   │   ├─ Mechanical failure: 30-40% over 10 years (catheter obstruction, disconnection)
│   │   │   ├─ Over-drainage ⭐:
│   │   │   │   ├─ Subdural hematoma (SDH): 5-10% (especially elderly, brain atrophy)
│   │   │   │   ├─ Slit ventricle syndrome: Collapsed ventricles, intermittent obstruction
│   │   │   │   └─ Management: ↑ valve pressure setting, anti-siphon device
│   │   │   ├─ Under-drainage: Recurrent symptoms, adjust valve to lower pressure
│   │   │   └─ Shunt malfunction: CT head (ventricular size), shunt series X-rays (integrity)
│   │   └─ Alternative: Endoscopic third ventriculostomy (ETV) - rarely effective in NPH
│   └─ Prognosis:
│       ├─ Early diagnosis and shunting: Better outcomes (before severe disability)
│       ├─ Secondary NPH: Better response than idiopathic (70-90% vs 50-70%)
│       └─ Predictors of good response: Gait-predominant, positive tap test, known etiology, short duration
│
└─ Congenital/pediatric hydrocephalus:
    ├─ Aqueductal stenosis: Most common cause (ETV effective, 70-80% success)
    ├─ Post-hemorrhagic (IVH of prematurity): VP shunt often required
    └─ Chiari malformation: Posterior fossa decompression (may resolve hydrocephalus)

---

This comprehensive specification provides ultra-granular coverage of fundamental neurosurgical knowledge including primary brain tumors (glioblastoma, oligodendroglioma, astrocytoma, meningioma, pituitary adenomas), metastatic brain tumors, cerebrovascular disease (intracranial aneurysms, SAH management), cavernous malformations, degenerative spine disease (lumbar disc herniation, spinal stenosis), traumatic brain injury, and hydrocephalus.

**CROSS-REFERENCES**:
- Imaging → LEVEL7_COMPLEX_NEUROANATOMICAL_IMAGE_ANALYSIS_COMPLETE.md
- Anatomy → All Level 3 anatomical specifications (vascular, white matter, functional, spine)
- Surgical approaches → Anatomical correlates in previous specifications

**TOTAL**: 1,722 lines of reference-grade neurosurgical pathology, pathophysiology, genetics, and treatment algorithms
